Is Wellbutrin (bupropion) safe during pregnancy, and are there concerns with increasing the dose to 450 mg daily?

Wellbutrin (Bupropion) Use in Pregnancy and Dose Escalation to 450mg

Bupropion can be continued during pregnancy at doses up to 450 mg daily when clinically necessary, as it does not appear to substantially increase the risk of major congenital malformations, though some specific cardiac defects warrant counseling. 1, 2

Overall Safety Profile

According to the most recent 2024 AJOG guidelines, bupropion does not seem to be associated with major congenital malformations or other significant adverse obstetrical outcomes, although data are limited 1. The FDA drug label confirms that epidemiological studies of pregnant women exposed to bupropion in the first trimester have not identified an increased risk of congenital malformations overall 2.

Key Safety Data:

• The international Bupropion Pregnancy Registry (675 first-trimester exposures) showed a cardiovascular malformation rate of 1.3%, which is similar to the background population rate of approximately 1% 2
• A systematic review found a pooled congenital malformation rate of only 1.0% (95% CI 0.0%-3.0%) among live births 3
• Mean birthweight (3305.9g) and gestational age (39.2 weeks) were within normal ranges 3

Specific Concerns to Discuss

Cardiovascular Malformations

There are conflicting data regarding specific cardiac defects that require transparent counseling:

Left Ventricular Outflow Tract Obstruction (LVOTO):

• One study (NBDPS) found increased risk (adjusted OR 2.6; 95% CI 1.2-5.6) with incidence of 0.279% vs 0.07% with other antidepressants 1
• However, other studies have not replicated this finding, and confounding by indication (depression, smoking) cannot be ruled out 1, 2

Ventricular Septal Defects (VSD):

• One case-control study found elevated risk (aOR 2.9; 95% CI 1.5-5.5), particularly with bupropion monotherapy (aOR 2.5; 95% CI 1.3-5.0) 1, 4
• This appears to be a dose-related phenomenon specific to bupropion alone rather than combination therapy 4

Diaphragmatic Hernia:

• One study suggested possible increased risk (aOR 2.77; 95% CI 1.34-5.71), but the absolute risk remains extremely small given the rarity of this defect (population prevalence 0.012%-0.031%) 1
• Other studies have not confirmed this association 1

Other Obstetrical Outcomes

• Spontaneous abortion: Possible increased risk, but this remains within general population rates and confounding by underlying depression cannot be excluded 1, 5
• Poor neonatal adaptation: Reported in limited cases, but data are insufficient to establish causation 1

Dosing Considerations for 450mg

The maximum recommended dose of 450 mg daily is explicitly stated in current guidelines and FDA labeling 1, 2. Important considerations:

Pharmacokinetics in Pregnancy:

• Pregnancy does NOT significantly alter bupropion metabolism or concentrations 6
• A 2021 study demonstrated no clinically meaningful changes in steady-state plasma concentrations, metabolite ratios, or clearance during pregnancy compared to postpartum 6
• Dose adjustment during pregnancy is generally not necessary based on pharmacokinetic data 6

Seizure Risk:

The primary concern with 450mg dosing is seizure risk, which increases at higher doses. While this is not pregnancy-specific, it warrants particular caution given potential fetal consequences. The FDA label emphasizes not exceeding 450 mg/day due to dose-dependent seizure risk 2.

Mania Risk:

Case reports suggest that doses exceeding 450 mg/day may be associated with manic switches in bipolar disorder, supporting a dose-related threshold phenomenon 7. Screen for bipolar history before escalating to maximum doses.

Clinical Decision Algorithm

When bupropion is needed during pregnancy:

1. Assess indication: Depression, ADHD, or smoking cessation

   • For smoking cessation specifically, note that a 2021 RCT found bupropion was NOT efficacious in pregnant women, though it was safe 8
   • For ADHD, guidelines suggest bupropion as an alternative to stimulants, though less efficacious 1

2. Counsel on specific risks:

   • Overall malformation risk: NOT substantially elevated
   • Specific cardiac defects (LVOTO, VSD): Small absolute risk increase, inconsistent data
   • Spontaneous abortion: Possibly elevated but within population norms
   • Emphasize that untreated maternal depression carries its own fetal risks 2

3. Dosing strategy:

   • Start at lowest effective dose (150-300 mg/day for XL formulation)
   • Titrate to 450 mg/day ONLY if clinically necessary for maternal functioning
   • Do NOT exceed 450 mg/day due to seizure risk
   • No pharmacokinetic-based dose adjustment needed during pregnancy 6

4. Monitoring:

   • Fetal growth surveillance (though growth restriction not consistently demonstrated)
   • Fetal echocardiography if first-trimester exposure and family/patient preference, focusing on LVOTO and VSD
   • Blood pressure monitoring (standard prenatal care)

5. Postpartum planning:

   • Continue same dose postpartum if effective
   • Breastfeeding: Caution advised—bupropion present in breast milk with 2 case reports of seizures in breastfed infants 1

Critical Pitfalls to Avoid

• Do not discontinue effective bupropion therapy solely due to pregnancy—untreated depression increases risk of relapse (women discontinuing antidepressants during pregnancy are more likely to relapse) 2
• Do not exceed 450 mg/day regardless of pregnancy status due to seizure risk
• Do not assume dose adjustment is needed based on pregnancy alone—pharmacokinetics remain stable 6
• Do not use bupropion as first-line for smoking cessation in pregnancy—efficacy data are lacking despite safety 8

Bottom Line

Bupropion at doses up to 450 mg daily can be safely continued during pregnancy when maternal mental health requires it, with informed consent about small, inconsistent risks of specific cardiac defects. The decision should prioritize maternal quality of life and functioning, as untreated depression poses its own risks to both mother and fetus. The 450 mg maximum dose is appropriate when clinically indicated, with no pregnancy-specific pharmacokinetic reason to reduce dosing.